Athira Pharma IPO

9/17/2020

IPO

$204,000,000

Management says it will use the net proceeds from the IPO as follows:approximately $75.0 million to fund the clinical development of ATH-1017 including the LIFT-AD trial and the ACT-AD P300 Phase 2 trial for the treatment of mild-to-moderate Alzheimer's disease;approximately $20.0 million to fund our planned Phase 2 trial of ATH-1017 for the treatment of Parkinson's disease dementia;approximately $30.0 million to fund our IND-enabling studies of ATH-1019 for the treatment of neuropsychiatric indications and ATH-1018 for the treatment of neuropathy; andthe remainder for our other research and development activities, as well as for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

4000 Mason Rd. 300 Box 352141
Seattle, WA 98195
USA

Athira Pharma (Nasdaq: ATHA) is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.